Valneva SE
Slēgts
2.18 1.87
Pārskats
Akcijas cenas izmaiņa
24h
Min
2.14
Max
2.14
Ienākumi | 18M -32M |
|---|---|
Pārdošana | -17M 31M |
EPS | -0.18 |
Peļņas marža | -103.783 |
Darbinieki | 674 |
EBITDA | 4.7M -20M |
Nākamie ieņēmumi | 2026. g. 13. aug. |
|---|
Tirgus kapitalizācija | -31M 459M |
|---|---|
Iepriekšējā atvēršanas cena | 0.31 |
Iepriekšējā slēgšanas cena | 2.18 |
Valneva SE Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
Valneva SE Prognoze
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$
Par Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.